



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Oliver Neckebrock, et al.

Confirmation No.: 8401

Application No.: 10/539,918

Group Art Unit: Not Yet Assigned

Filing Date: February 17, 2006

Examiner: Not Yet Assigned

For: PROCESS FOR THE PREPARATION OF AND CRYSTALLINE FORMS OF
OPTICAL ENANTIOMERS OF MODAFINIL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

Certification in Accordance with § 1.97(e) is attached; or

The fee of \$180.00 as set forth in § 1.17(p) is attached.

In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

Copies of reference numbers **1 – 13 and 21-25** listed on the attached Form PTO-1449 are enclosed herewith.

Copies of reference numbers **14 – 20** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: June 7, 2006


S. Maurice Valla
Registration No. 43,966

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2006 WW

Form PTO-1449 Modified		Docket No. CEPF-0006 (CP247)	Application No. 10/539,918
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			
U.S. Department of Commerce Patent and Trademark Office		Filing Date February 17, 2006	Not Yet Assigned
		Confirmation No. 8401	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Amiard, G., "No. 81.-Sur le dédoublement direct de la thréonine, par entraînement," <i>Bull. Soc. Chim. Fr.</i> , 1956, 447 (no English abstract)
2	Armodafinil Search, "Preliminary results from registry number search," April 10, 2006, 1-36 and 1-296
3	Bernstein, J., "Polymorphism in molecular crystals," <i>University Press, UK, 2002, Chapter 10</i> , 297-307
4	Coquerel, G., "Review on the heterogeneous equilibria between condensed phases in binary systems of enantiomers," <i>Enantiomers, Gordon & Breach Science Publishers, 2000</i> , 5, 481-498
5	Collet, A., et al., "Optical resolution by direct crystallization of enantiomer mixtures," <i>Chem. Rev.</i> , 1980, 80(3), 215-230
6	Courvoisier, L., et al., "Influence of the process on the mechanisms and the performances of the preferential crystallization: example with (±)-5-(4-Bromophenyl)-5-methylhydantoin," <i>Chemistry Letters</i> , 2001, 364-365
7	De Min., M., et al., "Chiral resolutions, asymmetric synthesis and amplification of enantiomeric excess," <i>J. Chem. Phys.</i> , 1988, 85, 603-619
8	Donovan, J.L., et al., "Chiral analysis of <i>d</i> - and <i>l</i> -modafinil in human serum: application to human pharmacokinetic studies," <i>Ther. Drug Monitoring</i> , 2003, 25, 197-202
9	In, Y., et al., "Crystal and molecular structure of an (S)-(+)-enantiomer of modafinil, a novel wake-promoting agent," <i>Chem. Pharm. Bull.</i> , 2004, 52(10), 1186-1189
10	Kim, S., et al., "A simple and mild esterification method for carboxylic acids using mixed carboxylic-carbonic anhydrides," <i>Am. Chem. Soc.</i> , 1985, 560-565
11	Ndzié, E., et al., "An efficient access to the enantiomers of α -methyl-4-carboxyphenylglycine via a hydantoin route using a practical variant of preferential crystallization AS3PC (auto seeded programmed polythermic preferential crystallization)," <i>Tetrahedron Asymmetry</i> , 1997, 8(17), 2913-2920
12	Prisinzano, T., et al., "Synthesis and determination of the absolute configuration of the enantiomers of modafinil," <i>Tetrahedron: Asymmetry</i> , 2004, 15, 1053-058
13	Raynal, H., et al., "Disposition of modafinil enantiomers in humans and dogs," <i>ISSX Proceedings, Fifth European ISSX Meeting, Tours, France, September 26-29, 1993</i> , 1 page

EXAMINER

DATE CONSIDERED

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER	DATE CONSIDERED
-----------------	------------------------